Kirk Taylor

Senior Vice President of North American Medical Affairs (NAMA)


Kirk Taylor is Senior Vice President of North American Medical Affairs (NAMA) at EMD Serono.

In this role, Kirk is responsible for leading the NAMA team with a focus on scientific communications, medical insights, and data generation to transform patient care.

Prior to his current role, Kirk served as Senior Vice President, Medical Affairs Strategy and Operations for Verastem Oncology, where he was responsible for developing medical launch strategies and driving data generation. Kirk also served as Chief of Strategy and Late Phase Development as well as Chief Medical Officer for Finch Therapeutics Group.

Kirk brings strong expertise as a practicing neurologist combined with 22 years of global and U.S. drug development experience in Phases I-IV across multiple therapeutic areas including Neurology, Oncology, as well as rare diseases.

Kirk holds an M.D. from State University of New York Downstate and a B.A. from Harvard University. He completed a neurology residency at the Albert Einstein College of Medicine and a postdoc in neuropathic pain and headache from the University of California at San Francisco.


You have accessed, but for users from your part of the world, we originally designed the following web presence

Let's go

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website. 

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement